A new systematic review and meta-analysis brings important clarity to a long-debated question in early-stage OCCC . Analyzing data from nine large non-RCTs, researchers found that adjuvant chemotherapy reduces the risk of recurrence by nearly 50% (HR 0.47) and may offer a meaningful overall survival advantage. The benefit is most pronounced in stage IC , where baseline recurrence risk is substantially higher. With 5-year DFS falling to 61% in untreated IC patients, the evidence highlights that chemotherapy can shift outcomes from high-risk to more controlled territory.
While stage IA gains are modest, the overall findings urge clinicians to weigh absolute risk carefully before opting for observation alone. To read more ; Click here What’s your current approach to stage I OCCC—treat or observe? ##Reference## Inayama, Yoshihide MD, PhD; Higashiyama, Nozomi MD; Yamaguchi, Ken MD, PhD;…
